This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
WHO–ISH Hypertension Guidelines Committee. 1999 World Health Organization – International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151–185.
Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755–1762.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–1252.
2003 European Society of Hypertension. European Society of Cardiology guidelines for management of arterial hypertension. J Hypertens 2003; 21: 1011–1053.
Burnier M, Brunner HR . Angiotensin II receptor antagonists. Lancet 2000; 355: 637–645.
Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–616.
Cook NR, Cohen J, Hekbert PR, Taylor JO, Hennekens CH . Implication of small reductions in diastolic blood pressure for primary prevention. Arch Int Med 1995; 155: 701–709.
Franklin SS, Khan SA, Wong ND, Larson MG, Levy D . Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study. Circulation 1999; 100: 354–360.
Staessen JA, Wang JG, Thijs L . Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358: 1305–1315.
Asmar R, Lacourciere Y . A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators. J Hypertens 2000; 18: 1683–1690.
Neutel JM . Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001; 87: 37C–43C.
Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–2031.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rump, L., Ambrosioni, E., Burnier, M. et al. Initial combination therapy with olmesartan/hydrochlorothiazide in moderate-to-severe hypertension. J Hum Hypertens 20, 299–301 (2006). https://doi.org/10.1038/sj.jhh.1001984
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1001984
This article is cited by
-
Olmesartan medoxomil: a guide to its use as monotherapy or in fixed-dose combinations with amlodipine and/or hydrochlorothiazide
Drugs & Therapy Perspectives (2016)
-
Antihypertensive drugs in combination: additive or greater than additive?
Journal of Human Hypertension (2007)
-
Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy
Advances in Therapy (2006)